Laura P Newman1, Anne Njoroge, Amalia Magaret, Bhavna H Chohan, Veronicah W Gitomea, Anna Wald, Jonathan Gorstein, Julie Overbaugh, Dalton Wamalwa, Elizabeth Maleche-Obimbo, Ruth Nduati, Carey Farquhar. 1. From the *Department of Global Health, University of Washington, Seattle, Washington; †Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya; ‡Department of Laboratory Medicine, University of Washington, §Department of Biostatistics, University of Washington, ¶Division of Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, ‖Department of Epidemiology, University of Washington, **Department of Medicine, University of Washington, ††Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and ‡‡Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington; and §§Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Abstract
BACKGROUND: There are limited data on whether HIV-infected children in resource-limited countries who are receiving antiretroviral therapy (ART) are able to produce sustained, protective levels of measles antibody after multiple measles vaccinations. METHODS: We administered an additional measles vaccine to HIV-infected children 15 months to 12 years of age receiving ART in Nairobi, Kenya. Measles antibody concentrations were determined by enzyme-linked immunosorbent assay at enrollment, 1 month, 12 months and 24 months post revaccination. RESULTS: At enrollment, 125 (54%) of 232 study participants had protective concentrations of measles antibody. Measles seropositivity increased to 98% of all children at 1 month post revaccination but decreased to 71% at 12 months and 60% at 24 months post revaccination. Measles seroconversion and sustained measles seropositivity among those who were measles seronegative at enrollment was 25% at 24 months post revaccination. In this group, 39% of children with <50 copies/mL plasma HIV RNA measles seroconverted compared to 4% of children with plasma HIV RNA ≥1000 copies/mL (P = 0.018). CONCLUSIONS: Measles revaccination can result in a sustained antibody response in a subset of HIV-infected children receiving ART, especially among those with HIV suppression.
BACKGROUND: There are limited data on whether HIV-infectedchildren in resource-limited countries who are receiving antiretroviral therapy (ART) are able to produce sustained, protective levels of measles antibody after multiple measles vaccinations. METHODS: We administered an additional measles vaccine to HIV-infectedchildren 15 months to 12 years of age receiving ART in Nairobi, Kenya. Measles antibody concentrations were determined by enzyme-linked immunosorbent assay at enrollment, 1 month, 12 months and 24 months post revaccination. RESULTS: At enrollment, 125 (54%) of 232 study participants had protective concentrations of measles antibody. Measles seropositivity increased to 98% of all children at 1 month post revaccination but decreased to 71% at 12 months and 60% at 24 months post revaccination. Measles seroconversion and sustained measles seropositivity among those who were measles seronegative at enrollment was 25% at 24 months post revaccination. In this group, 39% of children with <50 copies/mL plasma HIV RNA measles seroconverted compared to 4% of children with plasma HIV RNA ≥1000 copies/mL (P = 0.018). CONCLUSIONS:Measles revaccination can result in a sustained antibody response in a subset of HIV-infectedchildren receiving ART, especially among those with HIV suppression.
Authors: Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein Journal: J Infect Dis Date: 1990-11 Impact factor: 5.226
Authors: William J Moss; Susana Scott; Nanthalile Mugala; Zaza Ndhlovu; Judy A Beeler; Susette A Audet; Mirriam Ngala; Sheila Mwangala; Chansa Nkonga-Mwangilwa; Judith J Ryon; Mwaka Monze; Francis Kasolo; Thomas C Quinn; Simon Cousens; Diane E Griffin; Felicity T Cutts Journal: J Infect Dis Date: 2007-06-19 Impact factor: 5.226
Authors: Jared M Baeten; Barbra A Richardson; Daniel D Bankson; Mark H Wener; Joan K Kreiss; Ludo Lavreys; Kishorchandra Mandaliya; Job J Bwayo; R Scott McClelland Journal: Am J Clin Nutr Date: 2004-02 Impact factor: 7.045
Authors: Eleonora A M L Mutsaerts; Marta C Nunes; Martijn N van Rijswijk; Kerstin Klipstein-Grobusch; Diederick E Grobbee; Shabir A Madhi Journal: EClinicalMedicine Date: 2018-07-02